Remove Botox Remove Generic Drugs Remove Trials
article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business. Key drivers of the acquisition included Allergans robust product portfolio, particularly in ophthalmology, neuroscience and aesthetics.

Marketing 104
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Other drugs also contributed to Merck’s revenue growth. percent increase since 2021, predominantly due to Botox sales for therapeutic uses. billion, a decrease of 9.01

Sales 98